Actinium Pharma slips on late-stage cancer drug trial data

Actinium Pharmaceuticals

28/10/2019 16:39

** Drug developer's shares  ATNM.A  down 24% at 27 cents  
    ** Trading among top pct. losers across U.S. exchanges, set
for worst day in 6 months 
    ** Company on Monday reported results from its late-stage
trial to test its cancer treatment, iomab-B  urn:newsml:reuters.com:*:nPn2JgB1Ba
    ** Only 7 out of 38 patients enrolled in the trial achieved
an initial complete response and were able to proceed to bone
marrow transplant - ATNM
    ** More than 20k shares traded, 7.3x their 50-day moving
avg.
    ** The trial is evaluating the drug in patients aged 55 or
above with active and relapsed acute myeloid leukemia
    ** Including session's loss, ATNM down ~28% so far this year

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))